Find-A-Study

A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by extended treatment with open-label remibrutinib

Purpose

Category

IRB Number: 20210838HU
NCT Number: -
Sponsor: -

Study Contact

Principal Investigator
Tania Reyna

Sarah Martinez
210-450-0569
martinezs23@uthscsa.edu

Charlotte Rhodes
210-450-8454
rhodesc1@uthscsa.edu

Eligibility

Eligible Ages
Eligible Genders
Accepts Healthy Volunteers: No

Inclusion Criteria

Exclusion Criteria

Study Design

Arm Groups